• Mashup Score: 0

    This article summarizes the updated safety, overall response, and response durability in patients treated in the phase I dose-escalation part of the trial, presented at the 63rd ASH Annual Meeting and Exposition by Jeffrey Zonder.

    Tweet Tweets with this article
    • 📚The updated results from REGN5458 phase I study were presented by @Amyloid_Planet, @karmanoscancer at #ASH21. Read the latest on this novel BCMAxCD3 #bispecific antibody for R/R #myeloma, now recruiting for its phase II trial. 👉 https://t.co/s9aM0TO44z 👈 #mmsm https://t.co/MM3NEMbApd